Calcifediol

CHEMBL3544909 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
400.6 g/mol
LogP
6.2
Phase
4

A form of vitamin D that is the primary circulating storage form in the body, also known as 25-hydroxyvitamin D. It is used to treat secondary hyperparathyroidism and bone disease in patients with chronic kidney disease who have vitamin D deficiency. Unlike cholecalciferol, it does not require liver activation, making it useful in patients with liver disease.

分子量

400.6000 g/mol

LogP

6.20

TPSA

40.50 Ų

リピンスキーの五則

適合

治療領域

作用機序

Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12.O

InChI

InChI=1S/C27H44O2.H2O/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29;/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3;1H2/b21-11+,22-12-;/t20-,23+,24-,25+,27-;/m1./s1

Molecular Formula

C27H44O2

HBD / HBA

2 / 2

回転可能結合数

6

重原子数

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A form of vitamin D that is the primary circulating storage form in the body, also known as 25-hydroxyvitamin D. It is used to treat secondary hyperparathyroidism and bone disease in patients with chronic kidney disease who have vitamin D deficiency. Unlike cholecalciferol, it does not require liver activation, making it useful in patients with liver disease.

Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.

Yes, Calcifediol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3544909. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5283731. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.